Upfront Laparoscopic Management of Common Bile Duct Stones: What Are the Risk Factors of Failure?

Genet, Diane; Souche, Régis; Roucaute, S.; Borie, F.; Millat, Bertrand; Valats, Jean Christophe; Fabre, Jean‐Michel; Herrero, Astrid

doi:10.1007/s11605-023-05687-9

Cited by 3 publications

(1 citation statement)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cholecystolithiasis is a chronic recurrent hepatobiliary disease associated with impaired metabolism of cholesterol, bilirubin, and bile acids[ 1 , 2 ]. Age, sex, medications, diet, genetic factors, and factors associated with metabolic syndrome are risk factors for cholecystolithiasis and choledocholithiasis[ 3 ]. Patients with cholecystolithiasis and choledocholithiasis may present with clinical symptoms, including chills, fever, jaundice, biliary obstruction, epigastric pain, and cirrhosis, which pose a serious threat to the patient’s quality of life[ 4 ].…”

Section: Introductionmentioning

confidence: 99%

Clinical efficacy of laparoscopic cholecystectomy plus cholangioscopy for the treatment of cholecystolithiasis combined with choledocholithiasis

Liu,

Chen,

et al. 2024

World J Gastrointest Surg

View full text Add to dashboard Cite

BACKGROUND Currently, endoscopic retrograde cholangiopancreatography (ERCP) plus laparoscopic cholecystectomy (LC) is the main treatment for cholecystolithiasis combined with choledocholithiasis. However, the treatment is unsatisfactory, and the development of better therapies is needed. AIM To determine the clinical efficacy of LC plus cholangioscopy for cholecystolithiasis combined with choledocholithiasis. METHODS Patients (n = 243) with cholecystolithiasis and choledocholithiasis admitted to The Affiliated Haixia Hospital of Huaqiao University (910th Hospital of Joint Logistic Support Force) between January 2019 and December 2023 were included in the study; 111 patients (control group) underwent ERCP + LC and 132 patients (observation group) underwent LC + laparoscopic common bile duct exploration (LCBDE). Surgical success rates, residual stone rates, complications (pancreatitis, hyperamylasemia, biliary tract infection, and bile leakage), surgical indicators [intraoperative blood loss (IBL) and operation time (OT)], recovery indices (postoperative exhaust/defecation time and hospital stay), and serum inflammatory markers [C-reactive protein (CRP), tumor necrosis factor-α (TNF-α), and interleukin-6 (IL-6) were compared. RESULTS No significant differences in surgical success rates and residual stone rates were detected between the observation and control groups. However, the complication rate, IBL, OT, postoperative exhaust/defecation time, and hospital stays were significantly reduced in the observation group compared with the control group. Furthermore, CRP, TNF-α, and IL-6 Levels after treatment were reduced in the observation group compared with the levels in the control group. CONCLUSION These results indicate that LC + LCBDE is safer than ERCP + LC for the treatment of cholecystolithiasis combined with choledocholithiasis. The surgical risks and postoperative complications were lower in the observation group compared with the control group. Thus, patients may recover quickly with less inflammation after LCBDE.

show abstract